Navigation Links
PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Date:8/24/2009

OSLO, August 24 /PRNewswire/ -- PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation. The patient was treated at the University College Hospital (UCH) in London. PCI's proprietary photosensitiser Amphinex(R) is in this study combined with the therapeutic agent bleomycin. When activated by light, Amphinex(R) promotes effective delivery of large therapeutic molecules such as bleomycin through triggered endosomal release. The trial will investigate a broadly representative spectrum of cancers including head and neck cancer and breast cancer, to demonstrate the safety and potential of this new approach.

The primary objective of this study is to assess the maximum tolerated dose of Amphinex(R), in PCI treatment with bleomycin. Secondary objectives include determination of the antitumor activity of Amphinex(R) when used in combination with bleomycin, as well as its pharmacokinetics.

Colin Hopper, Principal Investigator at UCH, said: "At UCH we are dedicated to high quality patient care and we have extensive experience in the use of photodynamic therapy to treat cancer patients. PCI is a very exciting new approach in photodynamic medicine that has shown great promise in preclinical studies. We are very proud of being the first centre to move this new technology into the clinic."

Per Walday CEO of PCI Biotech, said: "This first in man trial is an important step forward for the company. We are confident that our approach addresses one major challenge in oncology - how to deliver therapeutics with large enough loads to effectively destroy tumours while at the same time reducing the risk of damaging healthy cells. Bleomycin is ideal for demonstrating this - there is no doubt about its therapeutic potential, but until now delivery problems and associated toxicity have prevented the realisation of its full potential. We expect to have the first preliminary results of the trial early in 2010."

In addition, whilst our main initial focus is cancer, we strongly believe the PCI technology also has potential to improve the effect of emerging treatments such as gene therapy and therapies based on nanotechnology or on biotechnological principles. In particular, we are looking at siRNA through projects funded by EU and by the Norwegian Research Council."


'/>"/>
SOURCE PCI Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
2. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
3. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
4. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
5. Biotech Hot in July Driven by Positive Drug Data and Acquisitions
6. Cardinal Health Completes Biotech Acquisition
7. Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
8. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
9. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
10. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
11. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... ... August 14, 2017 , ... Opal Kelly, a leading ... PCI Express, announced the release of SYZYGY™, a new open standard for connecting ... for a compact, low cost, low pin-count, high-performance connectivity solution between FPGAs and ...
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the community for more than ... important key elements including a new digital marketing strategy and updated logo. , As ... Miller has partnered with the South Texas Blood & Tissue Center for the month ...
(Date:8/10/2017)... ... 09, 2017 , ... As a full-service marketing agency, 212 ... with the right message. Their effective, cutting-edge inbound marketing strategies are available to ... crucial the agriculture industry is,” said David Phelps, chief marketing officer at 212 ...
(Date:8/10/2017)... ... ... Each year in the United States more than 300,000 people are hospitalized for ... even worse, the one-year mortality rate is high, ranging from 12 percent to 37 ... Medical Center (Sacramento) and Second Xiangya Hospital of the Central-South University (Hunan, China) might ...
Breaking Biology Technology:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):